Needham keeps Buy target at USD 204.00 for Neurocrine Biosciences stock

Published on 10/20/2026 at 19:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q3 results are due November 2, 2026. Neurocrine Biosciences stock costs EUR 125.40 on October 20, 2026.

Analyst target and reporting date

Needham reiterated a Buy rating and set a USD 204.00 target on October 16, 2026.
Neurocrine scheduled its third-quarter 2026 results for November 2, 2026.
Neurocrine Biosciences stock costs EUR 125.40 at Lang & Schwarz on October 20, 2026 at 7:19 p.m. CEST.

NBIX, US64125C1099, Illustration mit AI erstellt.

Neurocrine Biosciences (ISIN US64125C1099) received a reiterated Buy rating from Needham on October 16, 2026, with a USD 204.00 price target, according to Markets Insider. The target is 44.55 percent above Neurocrine's USD 141.13 Nasdaq price on October 20, 2026 at 1:29 p.m. ET. At Lang & Schwarz, the stock was trading at EUR 125.40 on October 20, 2026 at 7:19 p.m. CEST.

Revenue grew in the second quarter

Neurocrine reported USD 959.0 million in revenue for the second quarter ended June 30, 2026, compared with USD 687.5 million in the second quarter of 2025. That represents growth of 39.49 percent. Net profit reached USD 144.4 million, up 34.32 percent from USD 107.5 million a year earlier, according to Markets Insider.

Stock sits above its yearly low

The Nasdaq price of USD 141.13 on October 20, 2026 stood 15.55 percent above the 52-week low of USD 122.14 and 24.17 percent below the 52-week high of USD 186.12. Trading volume was 530,810 shares at 1:29 p.m. ET.

Valuation meets a near-term date

Neurocrine had a market capitalization of USD 14.4 billion and a price-to-earnings ratio of 20.66 on October 20, 2026. The next scheduled checkpoint is the third-quarter report on November 2, 2026. A Yahoo Finance report carrying the company release said the results are due at 4:00 p.m. ET, followed by a conference call at 4:30 p.m. ET.

What does the target imply?

Needham's USD 204.00 target leaves a USD 62.87 gap to the Nasdaq price of USD 141.13. The comparison uses the same currency, while the Lang & Schwarz quotation remains the euro price relevant for investors trading in Germany. Neurocrine's second-quarter revenue growth of 39.49 percent provides the operating figure behind the valuation discussion, but the upcoming report will determine whether that pace continued.

Euro quotation after hours

The stock was trading at EUR 125.40 at Lang & Schwarz on October 20, 2026 at 7:19 p.m. CEST. The euro quotation is an after-hours indication for investors in Germany.

The further course of trading is shown by the continuously updated real-time quote of Neurocrine Biosciences stock.